Company profile
Allurion Technologies Inc.
OTC: ALUR · Healthcare · Medical - Devices
PublicHQ Natick, MACIK 0001964979Reports USD
#582 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
26DFH 30DQ 16GM 30SS 37
v0.1 · 65/100 weight · provisional
↑ workforce scale, Piotroski F · ↓ balance-sheet leverage, disclosure history
Methodology →Revenue TTM
$12.6M
Rev growth YoY (TTM)
-55.5%
Net income (FY)
-$28.8M
Employees
40
as of 2026-08-24
Market cap
$4.7M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.2M$15.2M2025
Net income-$28.8M-$28.8M2025
Operating income-$30.2M-$30.2M2025
Total assets$15.8M$15.8M2025
Liabilities$93.0M$93.0M2025
Equity-$77.2M-$77.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Allurion Technologies Inc.’s revenue?
Allurion Technologies Inc. booked $15.2M in FY2025 revenue, contracting 53% year over year — slower than 82% of Healthcare companies we track, at a -188.8% net margin.
Peers · Healthcare
Green Growth Brands Inc.——Neuphoria Therapeutics Inc.44DRelay Therapeutics, Inc.57CVSee Health, Inc.35DLineage Cell Therapeutics, Inc.56CSunniva Inc.——Key facts
CEOShantanu K. Gaur
SectorHealthcare
IndustryMedical - Devices
HeadquartersNatick, MA
ExchangeOTC: ALUR
Employees40
IPO date2021-03-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.